Current price is more than the intrinsic value

Intrinsic Value

Returns vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

Dr. Srivari first joined as a Scientist in the Council of Scientific and Industrial Research – Indian Institute of Chemical Technology.

Dr Chandrashekhar Srivari resigns from Suven Pharma as Non-executive Independent Director

Suven Pharmaceuticals Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 13746.51 Crore) operating in Pharmaceuticals sector.

Buy Suven Pharma, target price Rs 600: ICICI Direct

Suven Pharma, Inc., will become an investor in the new company as part of deal.

Suven Pharma arm divests stake in US-based Rising Pharma Holdings

Suven Pharmaceuticals on Tuesday said wholly owned U.S. subsidiary Suven Pharma Inc. had divested its entire 25% stake in U.S. firm Rising Pharma Holdings Inc to Raisin Aggregator, L.P. USA, an arm o

Suven divests Rising stake in $56.4-mn deal

Suven Pharmaceuticals Ltd., incorporated in the year 2018, is a Small Cap company (having a market cap of Rs 12911.53 Crore) operating in Pharmaceuticals sector.

Buy Suven Pharmaceuticals, target price Rs 542: HDFC Securities

Suven Pharma Consolidated September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma Standalone September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma - Healthy Q2, Strong Traction In Specialty Chemical: Dolat Capital

Suven Pharmaceuticals fell 2.66% to Rs 502 after the company announced its earnings for the quarter ended 30 September 2021.

Suven Pharma slips after Q2 earnings

Revenue from operations rose to Rs 301 crore for the quarter under review, as against Rs 237 crore in the year-ago period, Suven Pharmaceuticals said in a regulatory filing.

Q2 Results: Suven Pharma Posts 31% Increase In Net Profit, Divi’s Labs Net Profit Rises 17%

Suven Pharmaceuticals on Saturday posted a 31% increase in its consolidated net profit to ₹97 crore for the second quarter ended September 30. Revenue from operations rose to ₹301 crore for the quarte

Suven Pharma Q2 profit rises 31% to ₹97 cr.

Suven Pharmaceuticals is engaged in  Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development

Suven Pharmaceuticals Ltd

Suven Pharmaceuticals Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Dr Chandrashekhar Srivari resigns from Suven Pharma as Non-executive Independent Director

Buy Suven Pharma, target price Rs 600: ICICI Direct

Suven Pharma arm divests stake in US-based Rising Pharma Holdings

Suven divests Rising stake in $56.4-mn deal

Buy Suven Pharmaceuticals, target price Rs 542: HDFC Securities

Suven Pharma Consolidated September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma Standalone September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma - Healthy Q2, Strong Traction In Specialty Chemical: Dolat Capital

Suven Pharmaceuticals Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Dr Chandrashekhar Srivari resigns from Suven Pharma as Non-executive Independent Director

Buy Suven Pharma, target price Rs 600: ICICI Direct

Suven Pharma arm divests stake in US-based Rising Pharma Holdings

Suven divests Rising stake in $56.4-mn deal

Buy Suven Pharmaceuticals, target price Rs 542: HDFC Securities

Suven Pharma Consolidated September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma Standalone September 2021 Net Sales At Rs 300.99 Crore, Up 26.79% Y-o-Y

Suven Pharma - Healthy Q2, Strong Traction In Specialty Chemical: Dolat Capital

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

Returns vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's return on equity is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock